Nuvation Bio Inc. (NUVB)
Upgrades & Downgrades
Latest NUVB news
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
27 June 2022
The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December...
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
21 January 2022
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
20 January 2022
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET fam...
Why Nuvation Bio Shares Are Rising
13 December 2021
Nuvation Bio Inc (NYSE:NUVB) shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422. "FDA clearance of our third IND application fo...
Nuvation Bio Appoints David C. Hanley, Ph.D.
1 June 2021
NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeu...
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
26 May 2021
NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeu...